TY - JOUR
T1 - Preventing Phosphorylation of the GABAAR β3 Subunit Compromises the Behavioral Effects of Neuroactive Steroids
AU - Vien, Thuy N.
AU - Ackley, Michael A.
AU - Doherty, James J.
AU - Moss, Stephen J.
AU - Davies, Paul A.
N1 - Funding Information:
This work was supported by the Sage Therapeutics, Inc., this funder contributed to the conception and design of the study. This study also received support from National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke Grants NS051195 (SM), NS056359 (SM), NS081735 (SM), NS087662 (SM), NS108378 (SM and PD), R21NS080064 (SM), R21NS111338 (PD), and R21NS111064 (PD), NIH, United States, and National Institute of Mental Health Grant MH097446 (SM and PD).
Publisher Copyright:
Copyright © 2022 Vien, Ackley, Doherty, Moss and Davies.
PY - 2022/3/31
Y1 - 2022/3/31
N2 - Neuroactive steroids (NASs) have potent anxiolytic, anticonvulsant, sedative, and hypnotic actions, that reflect in part their efficacy as GABAAR positive allosteric modulators (PAM). In addition to this, NAS exert metabotropic effects on GABAergic inhibition via the activation of membrane progesterone receptors (mPRs), which are G-protein coupled receptors. mPR activation enhances the phosphorylation of residues serine 408 and 409 (S408/9) in the β3 subunit of GABAARs, increasing their accumulation in the plasma membrane leading to a sustained increase in tonic inhibition. To explore the significance of NAS-induced phosphorylation of GABAARs, we used mice in which S408/9 in the β3 subunit have been mutated to alanines, mutations that prevent the metabotropic actions of NASs on GABAAR function while preserving NAS allosteric potentiation of GABAergic current. While the sedative actions of NAS were comparable to WT, their anxiolytic actions were reduced in S408/9A mice. Although the induction of hypnosis by NAS were maintained in the mutant mice the duration of the loss of righting reflex was significantly shortened. Finally, ability of NAS to terminate diazepam pharmacoresistant seizures was abolished in S408/9A mice. In conclusion, our results suggest that S408/9 in the GABAAR β3 subunit contribute to the anxiolytic and anticonvulsant efficacy of NAS, in addition to their ability to regulate the loss of righting reflex.
AB - Neuroactive steroids (NASs) have potent anxiolytic, anticonvulsant, sedative, and hypnotic actions, that reflect in part their efficacy as GABAAR positive allosteric modulators (PAM). In addition to this, NAS exert metabotropic effects on GABAergic inhibition via the activation of membrane progesterone receptors (mPRs), which are G-protein coupled receptors. mPR activation enhances the phosphorylation of residues serine 408 and 409 (S408/9) in the β3 subunit of GABAARs, increasing their accumulation in the plasma membrane leading to a sustained increase in tonic inhibition. To explore the significance of NAS-induced phosphorylation of GABAARs, we used mice in which S408/9 in the β3 subunit have been mutated to alanines, mutations that prevent the metabotropic actions of NASs on GABAAR function while preserving NAS allosteric potentiation of GABAergic current. While the sedative actions of NAS were comparable to WT, their anxiolytic actions were reduced in S408/9A mice. Although the induction of hypnosis by NAS were maintained in the mutant mice the duration of the loss of righting reflex was significantly shortened. Finally, ability of NAS to terminate diazepam pharmacoresistant seizures was abolished in S408/9A mice. In conclusion, our results suggest that S408/9 in the GABAAR β3 subunit contribute to the anxiolytic and anticonvulsant efficacy of NAS, in addition to their ability to regulate the loss of righting reflex.
KW - GABAergic inhibition
KW - anxiety
KW - drug-resistant seizures
KW - loss of consciousness
KW - neurosteroids
UR - http://www.scopus.com/inward/record.url?scp=85128451241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128451241&partnerID=8YFLogxK
U2 - 10.3389/fnmol.2022.817996
DO - 10.3389/fnmol.2022.817996
M3 - Article
C2 - 35431797
AN - SCOPUS:85128451241
SN - 1662-5099
VL - 15
JO - Frontiers in Molecular Neuroscience
JF - Frontiers in Molecular Neuroscience
M1 - 817996
ER -